Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) dropped 3.8% during mid-day trading on Friday . The stock traded as low as $24.95 and last traded at $26.66. Approximately 156,649 shares were traded during trading, an increase of 213% from the average daily volume of 50,104 shares. The stock had previously closed at $27.72.
Neoleukin Therapeutics Price Performance
The firm has a market cap of $251.40 million, a PE ratio of -8.60 and a beta of 1.11. The stock has a 50-day moving average price of $24.25 and a 200 day moving average price of $20.88.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Articles
- Five stocks we like better than Neoleukin Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- AI Demand Is Coming—Is Microchip Technology Ready?
- Options Trading – Understanding Strike Price
- Why Investors Have Flocked to 2 Unorthodox ETFs This Month
- What Are the U.K. Market Holidays? How to Invest and Trade
- Rivian’s Chart Says Go, But Some Analysts Still Say No
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
